Angiogenesis in Cardiovascular Disease

Moulton, Karen S.

doi:10.1002/9780470988473.ch4

Cited by 1 publication

(2 citation statements)

References 229 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo, VEGF has been shown to regulate vascular permeability, which is important for the initiation of angiogenesis by extravasating plasma proteins that form provisional matrix favoring cell migration 3 .…”

Section: Vascular Endothelial Growth Factor (Vegf)mentioning

confidence: 99%

“…FGFs mediate their effects via four tyrosine kinase receptors, FGFR1 to 4. 3 Human atherosclerosis tissues express increased FGF-1 compared with normal vessels, which may promote plaque revascularization and restenosis. FGF-1 & FGF -2 do not contain secretion signals, suggesting that cell injury is one mechanism for their release.…”

Section: Figure 3: Vegf Receptormentioning

confidence: 99%

See 1 more Smart Citation

Untitled

2012

IJPSR

View full text Add to dashboard Cite

Angiogenesis is process of new blood vessel formation that occurs under both normal and pathological conditions. In the normal state, two distinct processes can be seen. One utilizes endothelial progenitor cells (EPC) and the second utilizes existing vasculature to generate new vessels. The healthy body controls angiogenesis through a series of "on" (angiogenesisstimulating growth factors) and "off" (angiogenesis inhibitors) switches. However, the structures formed are often functionally abnormal; possibly due to an imbalance in the angiogenic process Angiogenesis represents an excellent therapeutic target for the treatment of cardiovascular disease. The healing of damaged tissues urgently required the rapid formation of new vessels which is brought about by various growth factors: VEGF, FGF, PDGF, Angiopoitins and Ephrins. Therapeutic angiogenesis is the clinical use of methods to enhance or promote the development of collateral blood vessels in ischemic, thrombotic, atherosclerotic tissue. This new form of treatment is an alternative to high risk percutaneous coronary intervention or coronary artery bypass surgery. There are three major ways to promote angiogenesis: protein therapy (by growth factor proteins including VEGF, bFGF), gene therapy (sustained production of angiogenic factors, the ability for local delivery and so less systemic exposure) and cellular therapy (monocytes, EPC and marrow stromal cells). INTRODUCTION:Angiogenesis is the process of new blood vessel formation as a natural event that occurs under both normal and pathological conditions. In the normal state, two distinct processes can be seen One that utilizes endothelial progenitor cells (EPC), these are usually derived from bone marrow and initiate endothelial growth and vascular tube formation & other one to utilizes existing vasculature to generate new vessels, and is highly dependent on endothelial cell activation and protease secretion. Under pathological conditions, many of the same steps involved in normal vessel formation are repeated.However, the structures formed are often functionally abnormal, possibly due to an imbalance in the angiogenic process.

show abstract

Section: Vascular Endothelial Growth Factor (Vegf)mentioning

confidence: 99%

Section: Figure 3: Vegf Receptormentioning

confidence: 99%